Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Paclitaxel 7Specimen Handling 6Radiotherapy 4Magnetic Resonance Spectroscopy 4Biopsy 4pembrolizumab 3Taxes 3Nivolumab 3Carboplatin 3trastuzumab deruxtecan 2olaparib 2ceralasertib 2aflibercept 2X-Rays 2Psychiatric Rehabilitation 2Irinotecan 2Ipilimumab 2Immunoglobulin G 2Ifosfamide 2Gene Expression Profiling 2Fulvestrant 2Filgrastim 2Fentanyl 2Doxorubicin 2Bevacizumab 2trifluridine tipiracil drug combination 1toripalimab 1tinostamustine 1spartalizumab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × TAS-116 × Sarcoma × Clear all
NCT05655598 2024-09-19

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Brown University

Phase 1 Withdrawn
GenitourinaryGynecologicSarcoma

Urinary Bladder Neoplasms, Sarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡